Craniofacial Morphogenesis in Prenatal Alcohol Exposure
Project Number5R01AA011085-08
Contact PI/Project LeaderSMITH, SUSAN M.
Awardee OrganizationUNIVERSITY OF WISCONSIN-MADISON
Description
Abstract Text
Prenatal alcohol exposure (PAE) is the leading known cause of mental retardation and birth defects. Its teratogenicity originates, in part, through its initiation of apoptosis in critical cell populations. Under previous NIAAA support, we developed a chick embryo model of PAE and showed that ethanol causes the selective apoptosis of the neural crest, an embryonic cell population containing craniofacial and neuronal precursors. Here, we hypothesize that ethanol induces neural crest apoptosis by activating the phospholipase C-dependent release of intracellular Ca2+. This hypothesis is tested using pharmacologic approaches, taking advantage that we can locally target agonists and antagonists of Ca2+ signaling pathways to the premigratory neural crest in ovo, and thus test their ability to attenuate ethanol's effects upon the embryo. Experiments in this proposal test three sub-hypotheses: 1) Acute ethanol induces neural crest apoptosis by stimulating the release of intracellular Ca2+. The requirement for Ca2+ release is tested through the use of fluorescent Ca2+ indicators, Ca2+ ionophores and chelators, and the direct assay of downstream, Ca2+-dependent signaling proteins (CaM kinase, calcineurin). 2) Ethanol mobilizes intracellular Ca2+ and induces apoptosis by activating inositol triphosphate (IP3) receptors. Pharmacologic agonists and antagonists test that the ethanol-released Ca2+ originates from IP3-mediated stores; this IP3 release will be quantified directly. Potential contributions of ryanodine receptors and extracellular Ca2+ also are tested. 3) Ethanol's activation of Phospholipase C (PLC) is responsible for the Ca2+ release and neural crest apoptosis. PLC activation is measured by direct assay and by targeted inhibitors. Contributions of diacylglycerol, receptor-mediated tyrosine kinases, and receptor-mediated G proteins are investigated. these results address the molecular mechanism underlying the neural crest's sensitivity to ethanol, and, thus, contribute to understanding the basis for ethanol's teratogenicity. Results also may provide possible explanations for genetic-based variations in fetal responses to prenatal ethanol exposure.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
G proteinapoptosisbiological signal transductionbone disordercalcineurincalcium channelcalcium fluxcalmodulin dependent protein kinaseconfocal scanning microscopycraniofacialdiacylglycerolsembryo /fetus toxicologyembryogenesisenzyme activityethanolfetal alcohol syndromehigh performance liquid chromatographyhistogenesisinositol phosphatesneural crestpathologic processphospholipase Cprotein tyrosine kinasethin layer chromatography
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
161202122
UEI
LCLSJAGTNZQ7
Project Start Date
01-July-1996
Project End Date
30-April-2006
Budget Start Date
01-May-2003
Budget End Date
30-April-2004
Project Funding Information for 2003
Total Funding
$311,459
Direct Costs
$225,000
Indirect Costs
$86,459
Year
Funding IC
FY Total Cost by IC
2003
National Institute on Alcohol Abuse and Alcoholism
$311,459
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AA011085-08
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AA011085-08
Patents
No Patents information available for 5R01AA011085-08
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AA011085-08
Clinical Studies
No Clinical Studies information available for 5R01AA011085-08
News and More
Related News Releases
No news release information available for 5R01AA011085-08
History
No Historical information available for 5R01AA011085-08
Similar Projects
No Similar Projects information available for 5R01AA011085-08